Nicole Mari Quintero, CRNP | |
1475 Taney Ave Ste 201, Frederick, MD 21702-5126 | |
(301) 662-0133 | |
Not Available |
Full Name | Nicole Mari Quintero |
---|---|
Gender | Female |
Speciality | Nurse Practitioner - Pediatrics |
Location | 1475 Taney Ave Ste 201, Frederick, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811589955 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | R256503 (Maryland) | Secondary |
363LP0200X | Nurse Practitioner - Pediatrics | R256503 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Nicole Mari Quintero, CRNP 1475 Taney Ave Ste 201, Frederick, MD 21702-5126 Ph: (301) 662-0133 | Nicole Mari Quintero, CRNP 1475 Taney Ave Ste 201, Frederick, MD 21702-5126 Ph: (301) 662-0133 |
News Archive
A new study by researchers at NYU Langone Medical Center reveals that the presence of Helicobacter pylori (H. pylori) bacteria is associated with elevated levels of glycosylated hemoglobin (HbA1c), an important biomarker for blood glucose levels and diabetes.
UC Davis Comprehensive Cancer Center received a $50,000 grant from the Safeway Foundation to explore the use of the South Asian spice Turmeric as a way of reducing joint pain in breast cancer patients being treated with anti-estrogen drugs.
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT), more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC).
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
› Verified 3 days ago